BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26497923)

  • 1. The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
    Giannatempo P; Pond GR; Sonpavde G; Raggi D; Naik G; Galsky MD; Bellmunt J; Necchi A
    Eur Urol; 2016 Apr; 69(4):624-633. PubMed ID: 26497923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study.
    Médioni J; Di Palma M; Guillot A; Spaeth D; Théodore C
    BMC Cancer; 2016 Mar; 16():217. PubMed ID: 26975779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience.
    Xue C; An X; Cao Y; Chen T; Yang W; Deng Y; Han H; Teng X; Zhou F; Shi Y
    Oncotarget; 2016 Sep; 7(39):63722-63729. PubMed ID: 27577082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
    Sonpavde G; Pond GR; Fougeray R; Choueiri TK; Qu AQ; Vaughn DJ; Niegisch G; Albers P; James ND; Wong YN; Ko YJ; Sridhar SS; Galsky MD; Petrylak DP; Vaishampayan UN; Khan A; Vogelzang NJ; Beer TM; Stadler WM; O'Donnell PH; Sternberg CN; Rosenberg JE; Bellmunt J
    Eur Urol; 2013 Apr; 63(4):717-23. PubMed ID: 23206856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy.
    Moriwaki T; Yamamoto Y; Gosho M; Kobayashi M; Sugaya A; Yamada T; Endo S; Hyodo I
    Br J Cancer; 2016 Apr; 114(8):881-8. PubMed ID: 27031848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.
    Viktorsson K; Shah CH; Juntti T; Hååg P; Zielinska-Chomej K; Sierakowiak A; Holmsten K; Tu J; Spira J; Kanter L; Lewensohn R; Ullén A
    Mol Oncol; 2016 May; 10(5):719-34. PubMed ID: 26827254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.
    Apolo AB; Ostrovnaya I; Halabi S; Iasonos A; Philips GK; Rosenberg JE; Riches J; Small EJ; Milowsky MI; Bajorin DF
    J Natl Cancer Inst; 2013 Apr; 105(7):499-503. PubMed ID: 23411591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of chemotherapy with or without anti-PD-1 for the first-line treatment of advanced urothelial carcinoma.
    Han F; Wu Z; Chen J; Liu M; Hu Y
    Cancer Med; 2023 Dec; 12(23):21129-21137. PubMed ID: 37990780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients.
    Roubaud G; Brouste V; Beuzeboc P; Fléchon A; Tosi D; Lavau-Denes S; Chevreau C; Culine S; Oudard S; Quivy A; Pourquier P; Houédé N
    J Negat Results Biomed; 2015 Nov; 14():18. PubMed ID: 26555878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic Organotropism Differential Treatment Response in Urothelial Carcinoma: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.
    Kardoust Parizi M; Matsukawa A; Bekku K; Klemm J; Alimohammadi A; Laukhtina E; Karakiewicz P; Chiujdea S; Abufaraj M; Krauter J; Shariat SF
    Eur Urol Oncol; 2023 Nov; ():. PubMed ID: 37980251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience.
    Ranganathan S; Riveros C; Xu J; Hu S; Geng M; Huang E; Melchiode Z; Zhang J; Efstathiou E; Chan KS; Wallis CJD; Sonpavde G; Satkunasivam R
    Urol Oncol; 2024 May; ():. PubMed ID: 38763801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter.
    Bianconi M; Cimadamore A; Faloppi L; Scartozzi M; Santoni M; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R
    Ther Adv Urol; 2019; 11():1756287218815372. PubMed ID: 30671136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic therapy for metastatic pancreatic adenocarcinoma.
    Lawrence B; Findlay M
    Ther Adv Med Oncol; 2010 Mar; 2(2):85-106. PubMed ID: 21789129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and taxanes in metastatic breast cancer: a systematic review.
    Gudena V; Montero AJ; Glück S
    Ther Clin Risk Manag; 2008 Dec; 4(6):1157-64. PubMed ID: 19337423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized therapy for urothelial cancer: review of the clinical evidence.
    Guancial EA; Chowdhury D; Rosenberg JE
    Clin Investig (Lond); 2011 Apr; 1(4):546-555. PubMed ID: 22754656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is my patient with urothelial cancer (in)eligible for platinum?
    Karahan I; Bilgin B
    Urol Oncol; 2024 Feb; 42(2):27. PubMed ID: 38195329
    [No Abstract]   [Full Text] [Related]  

  • 17. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
    Mateo J; Carreira S; Sandhu S; Miranda S; Mossop H; Perez-Lopez R; Nava Rodrigues D; Robinson D; Omlin A; Tunariu N; Boysen G; Porta N; Flohr P; Gillman A; Figueiredo I; Paulding C; Seed G; Jain S; Ralph C; Protheroe A; Hussain S; Jones R; Elliott T; McGovern U; Bianchini D; Goodall J; Zafeiriou Z; Williamson CT; Ferraldeschi R; Riisnaes R; Ebbs B; Fowler G; Roda D; Yuan W; Wu YM; Cao X; Brough R; Pemberton H; A'Hern R; Swain A; Kunju LP; Eeles R; Attard G; Lord CJ; Ashworth A; Rubin MA; Knudsen KE; Feng FY; Chinnaiyan AM; Hall E; de Bono JS
    N Engl J Med; 2015 Oct; 373(18):1697-708. PubMed ID: 26510020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
    Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
    Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical observation of docetaxel or gemcitabine combined with cisplatin in the chemotherapy after surgery for stage II-III non-small cell lung cancer.
    Chen QQ; Ji XX; Zhou X; Shi QL; Yu HM; Fu HQ; Ji GP
    Contemp Oncol (Pozn); 2015; 19(4):323-6. PubMed ID: 26557781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line treatment of metastatic gastric cancer: Current options and future directions.
    Kanagavel D; Fedyanin M; Tryakin A; Tjulandin S
    World J Gastroenterol; 2015 Nov; 21(41):11621-35. PubMed ID: 26556991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.